Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 4 (5), 507-30




Franjo Grotenhermen. Curr Drug Targets CNS Neurol Disord.


Since the discovery of an endogenous cannabinoid system, research into the pharmacology and therapeutic potential of cannabinoids has steadily increased. Two subtypes of G-protein coupled cannabinoid receptors, CB(1) and CB(1), have been cloned and several putative endogenous ligands (endocannabinoids) have been detected during the past 15 years. The main endocannabinoids are arachidonoyl ethanolamide (anandamide) and 2-arachidonoyl glycerol (2-AG), derivatives of arachidonic acid, that are produced "on demand" by cleavage of membrane lipid precursors. Besides phytocannabinoids of the cannabis plant, modulators of the cannabinoid system comprise synthetic agonists and antagonists at the CB receptors and inhibitors of endocannabinoid degradation. Cannabinoid receptors are distributed in the central nervous system and many peripheral tissues, including immune system, reproductive and gastrointestinal tracts, sympathetic ganglia, endocrine glands, arteries, lung and heart. There is evidence for some non-receptor dependent mechanisms of cannabinoids and for endocannabinoid effects mediated by vanilloid receptors. Properties of CB receptor agonists that are of therapeutic interest include analgesia, muscle relaxation, immunosuppression, anti-inflammation, antiallergic effects, improvement of mood, stimulation of appetite, antiemesis, lowering of intraocular pressure, bronchodilation, neuroprotection and antineoplastic effects. The current main focus of clinical research is their efficacy in chronic pain and neurological disorders. CB receptor antagonists are under investigation for medical use in obesity and nicotine addiction. Additional potential was proposed for the treatment of alcohol and heroine dependency, schizophrenia, conditions with lowered blood pressure, Parkinson's disease and memory impairment in Alzheimer's disease.

Similar articles

  • Pharmacology of Cannabinoids
    F Grotenhermen. Neuro Endocrinol Lett 25 (1-2), 14-23. PMID 15159677. - Review
    Dronabinol (Delta 9-tetrahydocannabinol, THC), the main source of the pharmacological effects caused by the use of cannabis, is an agonist to both the CB1 and the CB2 sub …
  • Cannabinoids and the Gut: New Developments and Emerging Concepts
    AA Izzo et al. Pharmacol Ther 126 (1), 21-38. PMID 20117132. - Review
    Cannabis has been used to treat gastrointestinal (GI) conditions that range from enteric infections and inflammatory conditions to disorders of motility, emesis and abdom …
  • Cannabinoids, Endocannabinoids, and Related Analogs in Inflammation
    SH Burstein et al. AAPS J 11 (1), 109-19. PMID 19199042. - Review
    This review covers reports published in the last 5 years on the anti-inflammatory activities of all classes of cannabinoids, including phytocannabinoids such as tetrahydr …
  • Endocannabinoid System: A Multi-Facet Therapeutic Target
    R Kaur et al. Curr Clin Pharmacol 11 (2), 110-7. PMID 27086601. - Review
    Cannabis sativa is also popularly known as marijuana. It has been cultivated and used by man for recreational and medicinal purposes since many centuries. Study of cannab …
  • The Endocannabinoid System: Physiology and Pharmacology
    F Rodríguez de Fonseca et al. Alcohol Alcohol 40 (1), 2-14. PMID 15550444. - Review
    The endogenous cannabinoid system is an ubiquitous lipid signalling system that appeared early in evolution and which has important regulatory functions throughout the bo …
See all similar articles

Cited by 24 PubMed Central articles

See all "Cited by" articles

MeSH terms